John Harrison

TL;DR: The effect on putative biomarkers for AD in CSF but not in plasma is suggestive of a central effect of the drug on Abeta metabolism, and the safety profile is favourable for the ongoing development of PBT2.

TL;DR: Receiver-operator characteristic analyses and ranking the responses to treatment after 12 weeks revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group, which further encourage larger-scale testing of P BT2 for AD.

TL;DR: Electroencephalography outcomes suggest that Souvenaid has an effect on brain functional connectivity, supporting the underlying hypothesis of changed synaptic activity.

TL;DR: There are no reliable prevalence or sex-ratio figures for synaesthesia, which is essential for establishing if the reported sex ratio (female bias) is reliable, and if this implicates a sex-linked genetic mechanism.

TL;DR: A study is presented in which nine subjects were tested who also reported having coloured hearing and confirmed the genuineness of these nine cases of chromatic–lexical synaesthesia, with some consistency found in the colours evoked by hearing specific letters, suggesting the condition has a neurological basis.